Cyllene
Paris, Ile-de-France, France · Biotechnology, Health Care, Therapeutics
Cyllene, previously known as EG 427, is a Paris-based biotechnology company focused on developing a genetic medicine platform for neurological diseases using non-replicating HSV-1 vectors. Its lead candidate, EG110A, targets bladder dysfunction in patients with spinal cord injuries. The company aims to achieve focal transduction and selective expression of transgenes in targeted subsets of neurons
Key facts
- Headquarters
- Paris, Ile-de-France, France
- Employees
- 400
- Industries
- Biotechnology, Health Care, Therapeutics
- Website
- groupe-cyllene.com
- Company page
Recent activity at Cyllene
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Cyllene funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series C | $37.6M |
Companies similar to Cyllene
- Crinetics Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Eikon Therapeutics · Biotechnology, Health Care, Therapeutics
- Amylyx Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Pharming Group · Biotechnology, Health Care, Therapeutics
- Tarsus Pharmaceuticals · Biotechnology, Health Care, Therapeutics
About Cyllene: questions and answers
What does Cyllene do?
Cyllene, previously known as EG 427, is a Paris-based biotechnology company focused on developing a genetic medicine platform for neurological diseases using non-replicating HSV-1 vectors. Its lead candidate, EG110A, targets bladder dysfunction in patients with spinal cord injuries. The company aims to achieve focal transduction and selective expression of transgenes in targeted subsets of neurons
Where is Cyllene headquartered?
Cyllene is headquartered in Paris, Ile-de-France, France.
How many employees does Cyllene have?
Cyllene has about 400 employees.
Has Cyllene raised funding?
Yes. Fundz has recorded 1 funding event for Cyllene. The most recent, Series C of $37.6M, was in Jul 2026.
What is the latest news on Cyllene?
On Jul 7, 2026, Cyllene, formerly EG 427, has raised €33m in a Series C funding round co-led by GordonMD Global Investments and M Ventures to advance its genetic medicine platform.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy